Editorial: Meningioma: From basic research to clinical translational study, volume II

Front Oncol. 2023 Mar 27:13:1150514. doi: 10.3389/fonc.2023.1150514. eCollection 2023.

Hailiang Tang^{1

2

3

4

5}, Zhewei Shen^{1

2

3

4

5}, David D Eisenstat^{6

7}, Ian F Dunn⁸

¹ Department of Neurosurgery, Huashan Hospital, Shanghai Medical College, Fudan University, Shanghai, China.
² National Center for Neurological Disorders, Shanghai, China.
³ Shanghai Key Laboratory of Brain Function and Restoration and Neural Regeneration, Shanghai, China.
⁴ Neurosugical Institute of Fudan University, Shanghai, China.
⁵ Shanghai Clinical Medical Center of Neurosurgery, Shanghai, China.
⁶ Department of Paediatrics, University of Melbourne, Parkville, VIC, Australia.
⁷ Murdoch Children's Research Institute, The Royal Children's Hospital Melbourne, Parkville, VIC, Australia.
⁸ Department of Neurosurgery, University of Oklahoma Health Sciences Center, Oklahoma City, OK, United States.

No abstract available

Keywords: cancer stem cells; genetic mutation; meningioma; molecular alteration; targeted therapy.

Publication types

DE is supported by an establishment grant from the Royal Children’s Hospital Foundation, Parkville VIC Australia (2019-1193).